Novo Nordisk stock surges 7% after Ozempic maker’s latest weight loss drug shows promise

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger. Read More

https://fortune.com/img-assets/wp-content/uploads/2025/01/GettyImages-2185288007-e1737737037243.jpg?resize=1200,600

2025-01-24 17:17:05